Axsome Therapeutics (AXSM) Earnings: What to Watch Before the Open
As seen on the 24/7 Wall St. homepage on August 10, 2026.
Axsome reports at 7:00 AM ET, confirmed, and the whole $10.9 billion valuation rides on Auvelity and Sunosi prescription growth holding pace with consensus. Guidance commentary here also sets the tone for the rest of the CNS group.
Continue ReadingShow less
Axsome Therapeutics is set to release its results at 7:00 AM ET on August 10, 2026, before the market opens. The report is confirmed, meaning investors won't be caught off guard by a surprise timing change, and attention will center squarely on prescription volume trends for Auvelity and Sunosi relative to what Wall Street has been modeling.
With a market valuation of $10.9 billion, the stakes are meaningful. Both Auvelity and Sunosi are the commercial engines driving that figure, so any sign that script growth is slipping against consensus estimates could put pressure on the stock. Conversely, results that pace with or beat expectations would validate the premium investors have already assigned to the company.
Beyond the headline numbers, guidance commentary will be closely parsed. Axsome operates in the central nervous system space, and what management says about the trajectory of its CNS portfolio tends to ripple across peer names in the group — making this report a read-through event for the broader sector, not just for AXSM holders.
Sources
Mentioned: AXSM